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The effect of long-term anticoagulation therapy
on bypass graft patency rates and on limb salvage rates
after infrainguinal arterial reconstruction remains
unresolved.1,2 Kretschmer et al3,4 demonstrated
improved graft patency rates and limb salvage rates
after femoropopliteal bypass grafting with autogenous
vein for patients who were randomized to undergo
long-term anticoagulation therapy with dicumarol. In
contrast, in a similar randomized trial, Arfvidsson et
al5 reported that the long-term use of dicumarol pro-
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Objective: Patients with marginal venous conduit, poor arterial runoff, and prior failed
bypass grafts are at high risk for infrainguinal graft occlusion and limb loss. We sought
to evaluate the effects of anticoagulation therapy after autogenous vein infrainguinal
revascularization on duration of patency, limb salvage rates, and complication rates in
this subset of patients.
Methods: This randomized prospective trial was performed in a university tertiary care
hospital and in a Veterans Affairs Hospital. Fifty-six patients who were at high risk for
graft failure were randomized to receive aspirin (24 patients, 27 bypass grafts) or aspirin
and warfarin (WAR; 32 patients, 37 bypass grafts). All patients received 325 mg of
aspirin each day, and the patients who were randomized to warfarin underwent antico-
agulation therapy with heparin immediately after surgery and then were started on war-
farin therapy to maintain an international normalized ratio between 2 and 3.
Perioperative blood transfusions and complications were compared with the Student t
test or with the c 2 test. Graft patency rates, limb salvage rates, and survival rates were
compared with the Kaplan-Meier method and the log-rank test.
Results: Sixty-one of the 64 bypass grafts were performed for rest pain or tissue loss, and
3 were performed for short-distance claudication. There were no differences between the
groups in ages, indications, bypass graft types, risk classifications (ie, conduit, runoff, or
graft failure), or comorbid conditions (except diabetes mellitus). The cumulative 5-year
survival rate was similar between the groups. The incidence rate of postoperative
hematoma (32% vs 3.7%; P = .004) was greater in the WAR group, but no differences
were seen between the WAR group and the aspirin group in the number of packed red
blood cells transfused, in the incidence rate of overall nonhemorrhagic wound compli-
cations, or in the overall complication rate (62% vs 52%). The immediate postoperative
primary graft patency rates (97.3% vs 85.2%) and limb salvage rates (100% vs 88.9%)
were higher in the WAR group as compared with the aspirin group. Furthermore, the
cumulative 3-year primary, primary assisted, and secondary patency rates were signifi-
cantly greater in the WAR group versus the aspirin group (74% vs 51%, P = .04; 77% vs
56%, P = .05; 81% vs 56%, P = .02) and cumulative limb salvage rates were higher in the
WAR group (81% vs 31%, P = .01).
Conclusions: Perioperative anticoagulation therapy with heparin increases the incidence
rate of wound hematomas, but long-term anticoagulation therapy with warfarin
improves the patency rate of autogenous vein infrainguinal bypass grafts and the limb
salvage rate for patients at high risk for graft failure. (J Vasc Surg 1998;28:446-57.)
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vided no benefits after infrainguinal bypass grafting
with either autogenous vein or expanded polytetraflu-
oroethylene prosthesis and was associated with a 
5% incidence rate for serious hemorrhagic complica-
tions. Furthermore, a recent multicenter randomized
prospective trial from Veterans Affairs Hospitals also
showed that long-term anticoagulation therapy with
warfarin did not improve primary assisted graft paten-
cy rates after infrainguinal bypass grafting with auto-
genous vein and that its use was associated with an
increased mortality rate and a significant incidence
rate for drug-related complications.6 However, the
conclusions from the Veterans Affairs Hospitals study
were confounded by the fact that 30% of the patients
who were randomized to undergo therapy with war-
farin either stopped taking the medication or had sub-
therapeutic international normalized ratio (INR) val-
ues at the time of graft failure.
If long-term anticoagulation therapy is of value
after infrainguinal arterial bypass grafting, it should
be most beneficial for the subset of patients who are
deemed to be at high risk for graft occlusion. This
subset includes those patients who have marginal
autogenous vein,7-10 poor distal arterial runoff,11,12
or previous failed bypass grafting procedures.13-16
Although both Robinson et al17 and Ala-Kulju et
al18 reported long-term anticoagulation therapy
with warfarin to be associated with a higher inci-
dence rate of graft failure after redo infrainguinal
arterial bypass grafting, both of these studies were
retrospective so that patient selection and other fac-
tors likely influenced these results. This study was
designed to prospectively evaluate the benefits of
long-term anticoagulation therapy after infrain-
guinal arterial bypass grafting with autogenous vein
in a subset of patients at high risk for graft failure.
We hypothesized that postoperative anticoagulation
therapy would improve both graft patency rates and
limb salvage rates in this subset of patients with an
acceptable risk of side effects.
PATIENTS AND METHODS
Experimental design. Patients who had under-
gone infrainguinal arterial revascularization with
autogenous vein and who were deemed at high risk
for graft occlusion were prospectively enrolled in the
study. After giving informed consent, the patients
randomly were assigned to undergo either long-term
anticoagulation therapy with warfarin plus aspirin
(WAR) or aspirin alone. The primary study endpoints
were a patent but failing graft, graft occlusion, and
death. The study was approved by the Institutional
Review Board of the University of Florida and the
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Subcommittee for Clinical Investigation of the
Veterans Affairs Hospital, Gainesville, Fla.
Enrollment criteria. All patients who under-
went infrainguinal arterial bypass grafting with auto-
genous vein at the Shands Hospital at the University
of Florida or at the Gainesville Veterans Affairs
Hospital between January 1993 and September
1995 were considered for the study. Patients were
excluded for the following reasons: pre-existing
medical indications for long-term anticoagulation
therapy; hematologic diathesis; a contraindication to
anticoagulation therapy, such as severe uncontrolled
hypertension or a prior history of intracranial, gas-
trointestinal, or genitourinary bleeding; an inability
to monitor the prothrombin time after surgery; or
an inability to obtain informed consent. Patients
were considered to be at high risk for graft failure if
one of the following criteria was satisfied: subopti-
mal venous conduit, poor arterial runoff, or redo
infrainguinal bypass grafting. The venous conduit
was considered suboptimal if it was less than 3.0 mm
in diameter with preoperative duplex ultrasound
mapping, if the vein was sclerotic with intraoperative
angioscopy, or if insufficient saphenous vein was
available, which would necessitate the use of arm
vein or a composite saphenous vein bypass graft.
Runoff was considered poor if the distal anastomot-
ic site of the bypass graft was in the distal one third
of the tibial or peroneal arteries, if there was runoff
to the foot only through collateral vessels, if the
anastomotic site was located in any portion of the
tibial or peroneal arteries and the entire runoff bed
was diffusely diseased with multiple sites of >50%
stenoses, or if selection of the distal target was com-
promised as a result of inadequate vein length such
that the anastomosis could not be placed beyond all
significant disease.
Procedures. All patients underwent a routine
preoperative evaluation that included a history and a
physical examination, a chest x-ray, an electrocardio-
gram, an echocardiogram, blood work, ankle
brachial indices, an arteriogram of the aorta and
runoff vessels with iodinated contrast or CO2,19 an
extremity vein map with duplex ultrasound scan-
ning,20 and selective cardiac tests.21 The arterial
reconstruction procedures were done with either gen-
eral inhalation or epidural anesthesia. The bypass
grafts were constructed with the vein in a nonreversed
fashion, and venous valves were lysed with a modified
Mill’s valvulotome. The completeness of the valvulo-
tomy was confirmed with video angioscopy for the
subset of patients who underwent bypass grafting
procedures at the Shands Hospital at the University
of Florida, and completion arteriography was used to
confirm valve lysis at the Veterans Affairs Hospital.
All patients underwent anticoagulation therapy with
heparin (100 units/kg) before arterial occlusion, and
the adequacy of the anticoagulation therapy was con-
firmed with the activated clotting time. The bypass
grafts were constructed with standard surgical tech-
niques, and arteriography or video angioscopy was
done at completion of the bypass grafting procedure
to assess its technical adequacy.22 Anticoagulation
therapy with heparin was not reversed at the comple-
tion of the procedure.
Experimental methods. Patient randomization
was performed with a computer-assisted random-
number generator (True Epistat, Richardson, Tex),
and the groups were matched for sex. If a patient
underwent bypass grafting in both lower extremities,
both bypass grafts were considered for that groups’
statistical comparison. All patients (both WAR group
and aspirin group) received 325 mg of aspirin per day,
beginning 1 day before the operation. The patients
who were randomized to WAR underwent anticoagu-
lation therapy with heparin (15 units/kg, continuous
drip) between 6 and 24 hours after the completion of
the bypass grafting procedure, and the activated partial
thromboplastin time (aPTT) was maintained at 1.5
times the control value. Oral anticoagulation therapy
with warfarin was begun for this group of patients on
postoperative day 2 or 3, and the warfarin dosage was
adjusted to maintain the INR between 2 and 3. INR
values were evaluated weekly in our anticoagulation
therapy clinics immediately after discharge and, once
the patient’s condition was stable, biweekly or month-
ly as long as the patient’s INR was therapeutic.
Patients in the WAR group were questioned about
warfarin compliance at each postoperative visit and
whenever their INR values were subtherapeutic. All
patients in the WAR group reported compliance with
warfarin administration. At each postoperative visit,
patients in both groups were questioned on their
compliance with aspirin therapy, and, similarly, all
patients reported complete compliance. However, sal-
icylate levels were not measured.
The patients were seen in the outpatient clinic
after hospital discharge at 2 weeks, 1 month, 3
months, 6 months, and every 6 months thereafter.
Ankle brachial indices and a duplex ultrasound graft
scan were obtained before hospital discharge and at
all outpatient clinic appointments after the initial
visit. Patients who had a decrease in their ankle
brachial indices of 0.15 or who had a duplex ultra-
sound graft scan examination that showed graft
velocities of more than 150 cm/seconds or less than
30 cm/seconds were considered to have failing
bypass grafts. The patients with failing grafts under-
went diagnostic arteriography, and if a stenosis of
>50% was identified, the grafts were revised with
either vein patch angioplasty or with an interposition
graft. Significant diseases in the inflow and runoff
arteries were also treated when appropriate. 
Patient demographics, comorbidities, operative
outcomes, and follow-up data were obtained from a
review of the preoperative data sheets, clinic charts,
and complete medical records. Complications were
defined with the National Veterans Affairs Surgical
Quality Improvement Program criteria,23 and the
operative mortality rate was defined with in-hospital
or 30-day mortality rates. Limb salvage rates and
graft patency rates were determined from recorded
results of physical examinations, ankle brachial
indices, duplex ultrasound graft scans, and arteri-
ograms. Survival data were completed with tele-
phone interviews of the patients or family members.
Data analysis. The data are presented and ana-
lyzed with the standards recommended by Rutherford
et al.24 Primary patency rate was defined as uninter-
rupted duration of patency without intervention.
Primary assisted patency rate was defined as uninter-
rupted duration of patency with intervention.
Secondary patency rate was defined as duration of
patency that was restored to the same conduit after
bypass graft occlusion. Three patients in the WAR
group stopped warfarin therapy because of a bleeding
complication, and 4 patients in the aspirin group were
placed on warfarin therapy after graft revision.
However, these patients were retained within their
original group on the basis of the intent-to-treat prin-
ciple, and exclusion of these patients in a separate
analysis did not change the results or the conclusions
of the study. Perioperative complications and the num-
ber of blood transfusions were compared with the 2-
tailed Student t test or with the c 2 test. Graft patency
rates, limb salvage rates, and survival rates were com-
pared with the Kaplan-Meier method and the log-rank
test. Univariate analysis and the Cox proportional haz-
ards regression model were used to analyze the effects
of comorbidities on graft patency rate. A value of P <
.05 was significant. Statistical analyses were performed
with the SPSS version 6.1 statistical software package
(SPSS Inc, Chicago, Ill).
RESULTS
Fifty-six patients who underwent 64 bypass
grafts were randomized to WAR or aspirin alone
(WAR, 32 patients and 37 bypass grafts; aspirin, 24
patients and 27 bypass grafts). These procedures
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comprised 15.1% of all the infrainguinal arterial
reconstructions done during the period of the study
(Veterans Affairs Hospital, 20/223 bypass grafts;
Shands Hospital 44/201 bypass grafts). No differ-
ences were seen between the 2 groups in age, sex,
and comorbidities except for diabetes mellitus
(Table I). Significantly more patients in the aspirin
group had diabetes mellitus, but analysis of the graft
patency rates, limb salvage rates, and survival rates
with the Cox proportional hazards regression model
showed that differences in this risk factor did not
change the overall results. The inclusion criteria
were equally distributed between the 2 groups
(Table II), with 24.2% of the patients in the WAR
group and 33.3% in the aspirin group fulfilling more
than 1 of these criteria. Sixty-one bypass grafting
procedures were done for rest pain or tissue loss 
and 3 for short-distance claudication. Overall, the
types of bypass grafting procedures done were
femoropopliteal (9%), femorotibial (72%), popliteal-
tibial (14%), and sequential femoropopliteal-tibial
(5%). No statistical differences were seen in the types
of bypass grafting procedures done in the WAR and
aspirin groups (Table II).
Only 1 perioperative death occurred in the WAR
group—the overall mortality rate was 1.8%—and the
postoperative mortality rates were not different
between the 2 groups. Postoperative morbidity rates
were also similar between the 2 groups, except for a
higher incidence rate of wound hematoma in the
WAR group (Table III). In addition, 4 of the 12
patients in the WAR group who developed a wound
hematoma required operative evacuation as com-
pared with no evacuations in the 1 patient in the
aspirin group in whom a wound hematoma devel-
oped (P = .07). Eight of the 13 patients with wound
hematomas had at least 1 aPTT that was more than
106 seconds in the first 48 hours after completion of
the bypass grafting procedure. However, no differ-
ences were seen between patients in the WAR and
aspirin groups in the number of packed red blood
cells transfused (2.8 vs 3.6 units, excluding wound
hematomas), or in the incidence rates of anticoagu-
lation therapy–related complications (gastrointesti-
nal, intracranial, and genitourinary hemorrhage;
13.5% in the WAR group, and 11.1% in the aspirin
group). Furthermore, the incidence rates of wound
infections or complications (41% vs 41%) and the
incidence rates of any complications (61% vs 52%)
were similar between the 2 groups.
Five bypass grafts occluded before hospital dis-
charge—4 in the aspirin group and 1 in the WAR
group. In addition, 3 amputations were necessary
before hospital discharge, all in the aspirin group.
Thus in the initial 7 postoperative days primary graft
patency rate was higher for the WAR group than for
Table III. Morbidity and mortality rates
WAR (%) ASA (%) P value
Perioperative mortality rate 1 (3) 0 (0) NS
(<30 days)
Myocardial infarction 1 (3) 2 (7) NS
Respiratory (pneumonia) 1 (3) 0 (0) NS
Hemorrhagic
Hematoma 12 (32)* 1 (4) .004*
Gastrointestinal 1 (3) 3 (11) NS
Central nervous system 1 (3) 1 (4) NS
Genitourinary 3 (9) 0 (0) NS
Wound 15 (41) 11 (41) NS
Overall 23 (62) 14 (52) NS
WAR, Patients who underwent therapy with warfarin and aspirin;
ASA, patients who underwent therapy with aspirin only; NS, not
significant.
*P < .05 with c 2 test.
Table I. Demographics and comorbidities
WAR (%) ASA (%) P value
Mean age 69.4 66.2 NS
Sex (M:F) 26:6 18:6 NS
Comorbidities
Hypertension 27 (84) 24 (100) NS
Coronary artery disease 24 (75) 21 (88) NS
Diabetes mellitus 17 (53) 19 (79) .05*
Tobacco abuse 31 (97) 18 (75) NS
Currently smoking 13 (41) 6 (25) NS
Renal insufficiency (Cr ‡ 1.6) 8 (25) 5 (21) NS
WAR, Patients who underwent therapy with warfarin and aspirin;
ASA, patients who underwent therapy with aspirin only; NS, not
significant; Cr, creatinine.
*P < .05 with c 2 test.
Table II. Bypass graft data
WAR (%) ASA (%) P value
Inclusion criteria
Poor runoff 9 (24) 10 (37) NS
Inadequate vein 14 (38) 14 (52) NS
Previous graft failure 24 (65) 13 (48) NS
>1 criterion 9 (24) 9 (33) NS
Bypass graft
Femoropopliteal 1 (3) 5 (19) NS
Femorotibial 28 (76) 17 (63) NS
Popliteal-tibial 6 (16) 3 (11) NS
Sequential femoropopliteal-tibial 2 (5) 2 (7) NS
WAR, Patients who underwent therapy with warfarin and aspirin;
ASA, patients who underwent therapy with aspirin only; NS, not
significant.
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the aspirin group (97.3% vs 85.2; P = .07), and the
limb salvage rate was significantly improved for the
WAR group compared with the aspirin group (100%
vs 88.9%; P = .04).
The 3-year primary graft patency rate was also
significantly higher in the WAR group as compared
with the aspirin group (74% vs 51%; P = .04) as seen
in Table IV and Fig. 1. Similarly, the 3-year primary
assisted graft patency rate (77% vs 56%; P = .05;
Table V; Fig. 2) and the secondary graft patency rate
(81% vs 56%; P = .01; Table VI; Fig. 3) were signif-
icantly greater in the WAR group. Furthermore,
there was a marked improvement in the 3-year limb
salvage rate in the WAR group as compared with the
aspirin group (81% vs 31%; P = .02; Table VII; Fig.
4). The improved primary assisted graft patency rate
and the secondary graft patency rate in the WAR
group appeared to be caused in part by the detection
of a significantly greater number of failing grafts as
compared with occluded grafts in the WAR group (5
failing, 5 occluded) as compared with the aspirin
group (1 failing, 10 occluded; P = .03). In addition,
4 of the 8 patients in the WAR group who were first
seen with an occluded graft had an INR of less than
1.5 within 1 month preceding graft failure. The
cumulative 5-year survival rates were similar in both
groups (Table VIII; Fig. 5).
DISCUSSION
In this study, postoperative anticoagulation thera-
py with heparin and aspirin followed by long-term
anticoagulation therapy with warfarin and aspirin
Fig. 1. Primary patency rate with Kaplan-Meier method
(log-rank test = 0.04). Dashed lines indicate standard error
greater than 10%.
Fig. 2. Primary assisted patency rate with Kaplan-Meier
method (log-rank test = 0.05).
Table IV, A. Primary patency rates with the Kaplan-Meier method for the patients who underwent 
therapy with warfarin and aspirin
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 37 1 0 0.03 97.3 2.7
0.2 36 0 1 0 97.3 2.7
1.0 35 1 1 0.03 94.5 3.7
1.1 33 0 1 0 94.5 3.7
3.0 32 1 2 0.03 91.5 4.7
4.0 29 0 1 0 91.5 4.7
5.0 28 2 0 0.07 85.0 6.2
6.0 26 0 2 0 85.0 6.2
7.0 24 1 1 0.04 81.5 6.9
8.0 22 1 1 0.05 77.8 7.5
9.0-41.9 18 1 17 0.06 74 8.1 
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Table V, A. Assisted primary patency rates with the Kaplan-Meier method for the patients who underwent
therapy with warfarin and aspirin
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 37 1 0 0.03 97.3 2.7
0.2 36 0 1 0 97.3 2.7
1.0 35 1 1 0.03 94.5 3.8
1.1 33 0 1 0 94.5 3.8
3.0 32 1 2 0.03 91.6 4.7
4.0 29 0 1 0 91.6 4.7
5.4 28 1 0 0.04 88.3 5.5
6.0 27 0 2 0 88.3 5.5
7.0 25 0 1 0 88.3 5.5
8.0 24 1 1 0.04 84.6 6.4
8.0 22 1 0 0.05 80.8 7.2
9.0-41.9 21 1 20 0.05 76.9 7.8
Table V, B. Assisted primary patency rates with the Kaplan-Meier method for the patients who underwent
therapy with aspirin only
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 27 1 0 0.04 96.3 3.6
0.1 26 1 0 0.04 92.6 5.0
0.2 25 1 0 0.04 88.9 6.1
1.2 24 0 1 0 88.9 6.1
1.5 23 0 1 0 88.9 6.1
2.0 22 1 2 0.05 84.9 7.0
2.1 19 1 0 0.05 80.4 7.9
3.0 18 1 0 0.06 75.9 8.7
4.0 17 1 0 0.06 71.5 9.2
5.0 16 0 1 0 71.5 9.2
6.0 15 1 0 0.07 71.5 9.2
6.0 14 2 2 0.14 61.9 10.2
6.9-31.0 10 1 9 0.10 56.3 10.7
Table IV, B. Primary patency rates with the Kaplan-Meier method for the patients who underwent 
therapy with aspirin only
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 27 2 0 0.07 92.6 5.0
0.13 25 1 0 0.04 88.9 6.1
0.02 24 1 0 0.04 85.2 6.8
1.2 23 0 1 0 85.2 6.8
1.5 22 0 1 0 85.2 6.8
2.0 21 1 0 0.05 81.1 7.6
2.0 20 1 2 0.05 77.1 8.3
3.0 17 1 0 0.03 72.5 8.9
4.0 16 1 0 0.06 68 9.5
5.0 15 0 1 0 68 9.5
6.0 14 1 0 0.07 68 9.5
6.0 13 1 2 0.08 58.3 10.3
8.0 10 0 2 0 58.3 10.3
9.0-31.0 8 0 8 0 51 11.3
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were found to improve the duration of graft patency
and the limb salvage rate after autogenous vein
infrainguinal bypass grafting for patients at high risk
for graft failure. These findings are consistent with
those of Kretschmer et al,3,4 who in a similar prospec-
tive randomized trial found that long-term anticoag-
ulation therapy with dicumoral improved femoro-
popliteal bypass graft patency rates primarily for
patients who underwent arterial reconstruction for
limb salvage (those most likely to have poor runoff).
The results reported here also confirm the findings of
Rosenthal et al,25 who in a post hoc analysis demon-
strated that a subgroup of patients at high risk for
graft failure were the ones most likely to benefit from
long-term anticoagulation therapy. In contrast, our
findings contradict the results from the other 2 ran-
domized studies on the use of long-term anticoagula-
tion therapy after infrainguinal arterial reconstruction
in which duration of graft patency and the limb sal-
vage rate were found to be equivalent in patients who
were treated as compared with the control group.
However, the patient population and the reconstruc-
tive procedures in the study by Arfvidsson et al5 were
considerably different from those reported here in
that only 26% of their patients had diabetes, at least
21% underwent treatment of intermittent claudica-
tion, 58% underwent either thromboendarterectomy
or prosthetic bypass grafting, and all but 9 underwent
femoropopliteal reconstruction. Furthermore, as pre-
viously noted, 30% of the patients who were random-
ized to long-term anticoagulation therapy in the study
by Johnson et al6 had stopped taking warfarin or had
a subtherapeutic INR at the time of graft failure.
Thus, our hypothesis that early and long-term antico-
agulation therapy would improve graft patency rates
and limb salvage rates for patients at high risk for graft
failure is supported by both the results presented here
and by those of previous studies in which such
patients were identified or included.
The combined use of warfarin and aspirin rather
than warfarin alone in the present study may 
have influenced our long-term results. Although
McCollum et al26 demonstrated that aspirin alone
Fig. 3. Secondary patency rate with Kaplan-Meier
method (log-rank test = 0.01).
Fig. 4. Limb salvage rate with Kaplan-Meier method
(log-rank test = 0.02). Dashed lines indicate standard error
greater than 10%.
Fig. 5. Survival rate with Kaplan-Meier method (log-rank
test = 0.21). Dashed lines indicate standard error greater
than 10%.
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 3 Sarac et al 453
did not alter infrainguinal vein graft patency rates,
immediate graft platelet uptake is inversely correlated
with 1-year graft patency rates27 and patients whose
platelets aggregate more readily are more likely to
suffer graft failure.28 In addition, warfarin combined
with aspirin has been found to be more effective in
preventing long-term prosthetic valve thromboem-
bolic complications as compared with warfarin alone,
without increasing the risk of bleeding complica-
tions.29 In the current study, long-term anticoagula-
tion therapy with warfarin and aspirin also did not
result in an increased incidence rate of bleeding com-
plications as compared with patients who were treat-
ed only with aspirin. However, the follow-up in our
study is relatively short and Fihn et al30 have shown
that the bleeding risk increases with the duration of
anticoagulation therapy. The yearly cumulative inci-
dence rate of hemorrhagic complications from long-
term warfarin use for medical purposes ranges
between 3% and 12%,31 and, despite the low inci-
dence rate of such complications in our patients,
long-term anticoagulation therapy for patients with
severe peripheral vascular disease is not without risk. 
Most infrainguinal vein graft failures occur in the
first 18 to 24 months after graft implantation, and in
this study, all the graft failures in both patient groups
occurred within the first 9 months of follow-up. The
Kaplan-Meier method graft patency rate curves were
essentially parallel after that period. A significant por-
tion of the improvement in duration of graft patency
for patients treated with warfarin plus aspirin also
appeared to be a result of detection and repair of fail-
ing grafts before graft occlusion. This suggests that
anticoagulation therapy for a finite period of time
after infrainguinal vein bypass grafting may be appro-
priate, which could limit difficulties and risks associat-
ed with long-term anticoagulation therapy. However,
an examination of the limb salvage rate curves in the
2 groups shows additional limb loss in the patients
who were treated with aspirin as compared with the
Table VI, A. Secondary patency rates with the Kaplan-Meier method for patients who underwent therapy
with warfarin and aspirin
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.2 37 0 1 0 100 0
1.0 36 1 1 0.03 97.2 2.7
1.1 34 0 1 0 97.2 2.7
3.0 33 0 2 0 97.2 2.7
4.0 31 0 2 0 97.2 2.7
5.4 29 1 0 0.03 97.2 2.7
6.0 28 0 2 0 97.2 2.7
7.0 26 0 1 0 93.9 4.2
8.0 25 1 1 0.04 93.9 4.2
8.0 23 1 0 0.04 93.9 4.2
9.0-41.9 22 1 21 0.05 82.3 7.3
Table VI, B. Secondary patency rates with the Kaplan-Meier method for patients who underwent therapy
with aspirin only
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 27 1 0 0.04 96.3 3.6
0.1 26 1 0 0.04 92.6 5.0
0.2 25 1 0 0.04 88.9 6.1
1.2 24 0 1 0 88.9 6.1
1.5 23 0 1 0 88.9 6.1
2.0 22 1 2 0.05 84.9 7.0
2.1 19 1 0 0.05 80.4 7.9
3.0 18 1 0 0.06 75.9 8.7
4.0 17 1 0 0.06 71.5 9.2
5.0 16 0 1 0 71.5 9.2
6.0 15 1 0 0.07 71.5 9.2
6.0 14 1 2 0.07 61.9 10.2
6.9-31.0 11 1 10 0.09 56.3 10.7
patients who were treated with warfarin and aspirin.
In addition, although no differences were seen
between secondary graft patency rates and limb sal-
vage rates for the patients treated with warfarin and
aspirin, there was a large difference in the secondary
graft patency rates and the limb salvage rates for the
patients treated with aspirin alone. Although the
numbers are small and the standard errors are large in
this portion of the actuarial analysis, these results sug-
gest that long-term anticoagulation therapy with war-
farin and aspirin may prevent limb loss, apart from
improving vein graft patency rates, possibly by limit-
ing the progressive occlusion of diseased runoff arter-
ies. Furthermore, Kretschmer et al32 have shown that
long-term anticoagulation therapy with warfarin
improves survival rates after femoropopliteal recon-
struction, and long-term use of aspirin has been
shown to decrease the risk of cardiac33 and cere-
brovascular events34 and to be of benefit for patients
with peripheral vascular disease.35,36
There was a high incidence rate of postoperative
wound hematomas for patients who were random-
ized to the WAR group, although the postoperative
wound complication rates were similar in both
groups and only 1 patient had a graft infection. This
was certainly a direct result of the anticoagulation
therapy with heparin in the immediate postoperative
period when the risk of wound bleeding was high. In
addition, the maintenance of precise control of the
level of anticoagulation therapy is often difficult
immediately after an operative procedure, and 8 of
the 13 patients who developed a wound hematoma
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Table VII, A. Limb salvage with the Kaplan-Meier method for patients who underwent therapy with 
warfarin and aspirin
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 37 0 1 0 100 0
0.2 36 0 1 0 100 0
1.0 35 0 2 0 100 0
1.1 33 1 0 0.03 97 3.0
3.0 32 0 3 0 97 3.0
4.0 29 0 1 0 97 3.0
5.0 28 1 1 0.04 93.5 4.5
6.0 26 0 2 0 93.5 4.5
7.0 24 1 1 0.04 89.6 5.7
8.0 22 1 1 0.05 85.5 6.8
9.0-41.9 20 1 19 0.05 81.3 7.7
Table VII, B. Limb salvage with the Kaplan-Meier method for patients who underwent therapy with
aspirin only
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.03 27 2 0 0.07 92.6 5.0
0.13 25 1 0 0.04 88.9 6.1
0.2 24 0 1 0 88.9 6.1
1.2 23 0 1 0 88.9 6.1
1.5 22 1 0 0.05 84.9 7.0
2.0 21 1 3 0.05 80.8 7.7
3.0 17 1 0 0.06 80.8 7.7
4.0 16 1 0 0.06 76.1 8.6
5.0 15 0 1 0 71.3 9.3
6.0 14 0 3 0 71.3 9.3
8.0 11 0 2 0 71.3 9.3
9.0 9 0 1 0 71.3 9.3
13.4 8 0 1 0 71.3 9.3
19.9 7 1 0 0.14 71.3 9.3
21.0 6 0 2 0 61.1 12.4
23.0 4 0 1 0 61.1 12.4
27.0 3 0 1 0 61.1 12.4
29.9 2 1 0 0.50 61.1 12.4
31 1 0 1 0 30.1 22.4
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had an aPTT that was well above the therapeutic
range within the first 48 hours after surgery. A delay
of the initiation of postoperative anticoagulation
therapy with heparin or a decrease in the heparin
dose may limit the incidence rate of wound
hematoma without an adverse impact on early dura-
tion of graft patency. Alternatively, the use of intra-
venous high molecular–weight dextran37 or ticlopi-
dine hydrochloride38 in the immediate postoperative
period and the delay of anticoagulation therapy with
warfarin and aspirin until just before hospital dis-
charge may achieve the same result. Whether either
of these approaches will result in the improved post-
operative bypass graft patency rates and limb salvage
rates seen in patients who undergo anticoagulation
therapy with heparin and aspirin remains to be
determined. Ticlopidine hydrochloride has also been
shown to improve long-term saphenous vein bypass
graft patency rates.38 However, whether ticlopidine
hydrochloride would improve graft patency rates
and limb salvage rates to the same degree that war-
farin does for patients at high risk for graft failure is
unknown.
In conclusion, the benefits of early and long-term
anticoagulation therapy after infrainguinal bypass
grafting in a subset of patients at increased risk for
graft failure have been shown. Early postoperative
anticoagulation therapy with heparin was shown to
increase the risk of wound hematomas but not wound
or graft infection, and long-term anticoagulation
Table VIII. Survival rates with the Kaplan-Meier method for patients who underwent therapy with 
warfarin and aspirin
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
0.2 32 1 0 0.03 96.9 3.1
1.0 31 0 1 0 96.9 3.1
4.0 30 0 1 0 96.9 3.1
6.0 29 1 0 0.03 93.5 4.4
7.0 28 0 1 0 93.5 4.4
8.0 27 0 1 0 93.5 4.4
8.0 26 1 0 0.04 89.9 5.5
17.0 25 1 0 0.04 86.3 6.4
22.0 24 0 1 0 86.3 6.4
23.9 23 0 2 0 86.3 6.4
24.7 21 0 1 0 86.3 6.4
25.0 20 1 0 0.05 82.0 7.4
25.9-44.9 19 0 16 0 82.0 7.4
47.9-51.9 3 1 2 0.33 54.7 22.9
Table VIII, B. Survival rates with the Kaplan-Meier method for patients who underwent therapy with
aspirin only
Event time No. at risk Cumulative 
(months) at event No. of events Withdrawn Failure rate patency rate (%) Standard error (%)
1.2 24 0 1 0 100 0
2.0 23 1 0 0.04 95.7 4.3
3.0 22 1 0 0.05 91.3 5.9
5.0 21 0 1 0 91.3 5.9
6.0 20 0 1 0 91.3 5.9
12.0 19 1 0 0.05 86.5 7.3
13.4 18 0 1 0 86.5 7.3
15.0 17 1 0 0.06 81.4 8.4
19.9 16 1 0 0.06 76.3 9.3
21.0 15 0 1 0 76.3 9.3
23.0 13 1 1 0.08 70.9 10.1
25.9 12 0 1 0 70.9 10.1
27.0 11 0 1 0 70.9 10.1
27.9 10 0 1 0 70.9 10.1
29.9 9 1 1 0.11 63 11.7
31.0 7 0 2 0 63 11.7
33.9-51.9 5 1 4 0.20 50.4 14.6
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therapy was not associated with an increased risk of
hemorrhagic complications. Therefore, the routine
use of warfarin and aspirin for patients at a high risk
for infrainguinal bypass graft failure appears justified,
but the best method for maintaining immediate post-
operative graft patency duration and the limb salvage
rate in such patients remains to be determined.
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